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Lessons from the field
Problem As national antiretroviral treatment (ART) programmes scale-up, it is essential that information is complete, timely and 
accurate for site monitoring and national planning. The accuracy and completeness of reports independently compiled by ART 
facilities, however, is often not known.
Approach This study assessed the quality of quarterly aggregate summary data for April to June 2006 compiled and reported by ART 
facilities (“site report”) as compared to the “gold standard” facility summary data compiled independently by the Ministry of Health 
supervision team (“supervision report”). Completeness and accuracy of key case registration and outcome variables were compared. 
Data were considered inaccurate if variables from the site reports were missing or differed by more than 5% from the supervision 
reports. Additionally, we compared the national summaries obtained from the two data sources.
Local setting Monitoring and evaluation of Malawi’s national ART programme is based on WHO’s recommended tools for ART 
monitoring. It includes one master card for each ART patient and one patient register at each ART facility. Each quarter, sites complete 
cumulative cohort analyses and teams from the Ministry of Health conduct supervisory visits to all public sector ART sites to ensure the 
quality of reported data.
Relevant changes Most sites had complete case registration and outcome data; however many sites did not report accurate data for 
several critical data fields, including reason for starting, outcome and regimen. The national summary using the site reports resulted in 
a 12% undercount in the national total number of persons on first-line treatment. Several facility-level characteristics were associated 
with data quality.
Lessons learned While many sites are able to generate complete data summaries, the accuracy of facility reports is not yet 
adequate for national monitoring. The Ministry of Health and its partners should continue to identify and support interventions such 
as supportive supervision to build sites’ capacity to maintain and compile quality data to ensure that accurate information is available   
for site monitoring and national planning.
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Problem
By 31 December 2006, Malawi had 
enrolled 82 000 patients in its free 
national antiretroviral treatment (ART) 
programme. Each quarter, data from all 
ART clinics are aggregated for national 
reporting on ART scale-up. This infor-
mation is essential to monitoring site 
performance, guiding national planning 
and supporting sustained funding.
Despite increasing reliance on sites 
to aggregate data, the completeness and 
accuracy of sites’ reports was unknown. 
We therefore conducted an operational 
study during regular supervisory visits 
to assess the quality of data in the site 
reports. Specific objectives were to: 
i) determine the completeness and 
accuracy of key case registration and 
outcome data compiled by ART clinics, Lessons from the field
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ii) compare national data summarized 
from site reports versus supervision 
reports, and iii) analyse characteristics 
associated with sites’ capacity to com-
pile quality data.
Local setting
A standardized monitoring and evalua-
tion (M&E) system is key to Malawi’s 
national ART programme.1–3 The sys-
tem is based on WHO’s recommended 
tools for ART monitoring, and includes 
one master card for each ART patient 
and one patient register at each ART fa-
cility. At each ART clinic visit, patients 
are monitored according to standard 
primary and secondary outcomes. Each 
quarter, sites are asked to complete cu-
mulative cohort analyses, summarizing 
the characteristics and outcomes of all 
patients ever enrolled at the site. Each 
quarter, the Ministry of Health and its 
partners conduct supervisory visits to all 
public sector ART sites, during which 
the supervision teams review all patient 
master cards with clinic staff, update 
the ART patient registers, and inde-
pendently generate cumulative cohort 
analyses for each site. These visits ensure 
the quality of reported data.4
Approach
The Ministry of Health HIV/AIDS 
Unit and partners conducted supervi-
sory visits, during July and August 2006, 
to assess case registration and patient 
outcome information as of 30 June 
2006. At the beginning of the visit, site 
reports completed by facility staff were 
collected. All patient master cards were 
reviewed, registers updated as appropri-
ate and the cumulative cohort analysis 
was aggregated by the clinic and super-
vision team together to generate the 
supervision report. Data from site and 
supervision reports were analysed with 
SPSS (Statistical Package for Social Sci-
ences 2006, SPSS Inc. Chicago, Illinois, 
United States of America).
By 30 June 2006, 56 000 persons 
had started treatment in 94 public 
sector sites. Five sites (5%) had elec-
tronic data systems for ART reporting 
and were excluded from the analyses. 
Analysis of site report data was there-
fore conducted on the 89 sites that   
were expected to have completed a 
paper-based analysis.
Completeness and accuracy of data 
from site reports were compared to 
that of supervision reports for six case-
registration variables (total patients 
ever started on ART, and of those, the 
number who were men; children; teach-
ers among all occupation categories; 
patients in WHO clinical stage 4 at 
ART initiation; and patients with his-
tory of tuberculosis) and two outcome 
variables (total patients alive on ART and 
the number on first-line regimen). Data 
were considered complete if sites had 
recorded any value for a specific field;   
data were considered accurate if none of 
the examined variables in the site report 
were missing or showed a difference of 
more than 5% compared to the super-
vision report. In addition to site-level 
analyses, national totals summarized 
from site reports were compared with 
totals from supervision reports.
We examined whether site charac-
teristics such as facility-type, burden 
(maximum number of new patients the 
clinic can start each month), length of 
time providing treatment, and number 
of data clerks were associated with com-
plete and accurate data in sites’ reports 
using binary logistic regression.
Findings and relevant 
changes
Data completeness
Sixty-two (70%) sites provided com-
plete data for all six case-registration 
fields in the site report. Aggregates for 
the number of patients starting ART 
because of tuberculosis history and pa-
tient occupation were least likely to be 
complete with 26 (29%) and 21 (24%) 
sites having incomplete information for 
these fields, respectively. Outcome data 
were complete at 71 (80%) sites.
Data accuracy
The accuracy of many site reports was 
classified as unacceptable (data missing 
or > 5% difference compared to super-
vision report). Case registration data 
were accurate in only 36 (40%) sites. 
Fields less accurately reported included 
numbers of patients in clinical stage 4 
at ART initiation, patients with history 
of tuberculosis, and male patients, with 
33 (37%), 29 (33%), and 12 (25%) sites 
reporting inaccurate data respectively.
Sixty-four (72%) sites reported ac-
curate outcome data on the cumulative 
number of patients alive and on ART 
and number of patients on first-line 
regimen at the end of the quarter.
Accuracy of national summary 
figures using site report data
Outcome data were added for the 89 
sites and summary totals from site and 
supervision reports compared. The na-
tional summary of persons alive and on 
ART, based on site report data, resulted 
in a 5.4% undercount (22 390 patients 
in site reports versus 23 665 from su-
pervision reports.) The national figures 
for patients on first-line regimen were   
20 500 patients in the site report versus 
23 380 patients in the supervision re-
port, an underestimate of 12.3%.
Association between facility 
characteristics and data quality
Table 1 presents the relationship be-
tween facility characteristics and the 
completeness and accuracy of outcome 
data. Several factors were associated 
with quality data, including a higher 
burden (starting more patients each 
month), having dedicated clerks for 
recordkeeping, having a visit by a zonal 
ART supervisor before the national su-
pervision visit, being located in the cen-
tral or southern region, having provided 
ART for a longer period of time, and 
being a type of facility other than a rural 
hospital or health centre. It should be 
noted that all rural hospitals and health 
centres are low burden, thus have simi-
lar odds ratios. Further analysis revealed 
that the length of time a facility had 
provided ART explained the association 
between burden and data quality due to 
the correlation between site burden and 
length of time that sites had provided 
treatment.
Lessons learned
In many national health information 
systems, sites routinely collect and report 
summarized data. This was the first sys-
tematic audit of routinely reported data 
generated by ART sites using Malawi’s 
national ART M&E system. Based on 
thresholds of accuracy considered criti-
cal for programme planning, this audit 
shows that, at the national level, the 
ART programme in Malawi still requires 
skilled assistance to compile reliable 
data. Data quality varied considerably 
between sites and was associated with 
facility characteristics. While some 
factors, such as the length of time sites 
have been providing treatment, are not 
easily changed, other “actionable” fac-
tors, including supervision and human 
resources for record keeping (clerks) 312 Bulletin of the World Health Organization | April 2008, 86 (4)
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Table 1. Sites with acceptable data quality




Data completeness Data accuracy
Number (and 
proportion) 
of sites with 
complete 
outcome data




of sites with 
accurate 
outcome data
Odds ratio (90% 
confidence interval)
Burden
Medium or medium-high burden 
(max. 50 or 75 new patients/month)
30 28 (0.93) ref 27 (0.90) ref
Low burden (max. 25 new patients/
month)
59 43 (0.73) 0.19 (0.05–0.70)
a 37 (0.63) 0.19 (0.06–0.56)
a
Type
Central or district hospital 22 20 (0.91) ref 19 (0.86) ref
Mission hospital 26 21 (0.81) 0.42 (0.10–1.83) 19 (0.73) 0.43 (0.12–1.50)
Rural hospital or health centre 20 14 (0.70) 0.23 (0.05–1.00) 11 (0.55) 0.19 (0.06–0.68)
a
Other (NGO, military) 21 16 (0.76) 0.32 (0.07–1.41) 15 (0.71) 0.40 (0.11–1.44)
Region
Southern 35 33 (0.94) ref 29 (0.83) ref
Central 37 28 (0.76) 0.19 (0.05–0.73)
a 28 (0.76) 0.64 (0.24–1.70)
Northern 17 10 (0.59) 0.09 (0.02–0.37)
b 7 (0.41) 0.15 (0.05–0.43)
Number of clerks for record-keeping
c
None 6 4 (0.67) ref 3 (0.50) ref
1 clerk 66 52 (0.79) 3.90
d (1.30–11.69)
a 47 (0.71) 3.55
d (1.32–9.55)
a
2 clerks 15 15 (1.00) 14 (0.93)
Length of time site providing treatment
0–3 months 33 20 (0.61) ref 15 (0.46) ref
4–12 months 27 24 (0.89) 5.20 (1.62–16.68)
a 24 (0.90) 9.60 (2.61–21.56)
b
13 or more months 29 27 (0.93) 8.77 (2.30–33.51)
b 25 (0.86) 7.50 (3.01–30.62)
a
Previous supervision visit in the quarter
No supervision 61 47 (0.77) ref 41 (0.67) ref
Supervision 28 24 (0.86) 1.79 (0.64–4.95) 23 (0.82) 2.24 (0.89–5.68)
NGO, nongovernmental organization; ref, reference.
a  P < 0.05.
b  P < 0.01.
c  No information on clerks at two sites.
d  Odds ratio shows the increase in odds for every additional clerk.
were associated with increased data   
quality. Sites with longer experience 
in providing ART were more likely to 
generate quality data, which may be 
attributed to the intensive quarterly su-
pervision that sites have received. With 
rural hospitals and health centres found 
to have lower quality data than other 
hospital types, a better understanding 
of what specific characteristics (e.g. 
burden, staffing levels, management, 
incentives) impact data quality at the 
facility is needed.
Errors in site report data did impact 
national totals: national totals of persons 
currently on treatment and persons on 
first-line regimen were undercounted by 
more than 5% and 12%, respectively, 
when national figures were derived 
from site reports. Left uncorrected, the 
difference between reported and true 
figures would likely increase over time. 
Since drug orders are based on these 
national summary data, errors in the 
number of patients on first-line regi-
men would underestimate the quantity 
of first-line ARV drugs needed annually 
by nearly 35 000 tins. Malawi has not 
yet stocked out of ARV drugs, and an 
adequate drug supply is critical to the 
continued scale-up of the programme.
Analyses were based on data from 
supervisory visits as the gold standard; 
given the number of records to be re-
viewed during supervision visits (30 sites 
have started more than 500 patients), 
some errors may have been made dur-
ing supervision. Still, the effect is likely 
to be small. This study assessed data 
completeness and accuracy of aggre-
gated facility-level data; the accuracy of 
individual patient information, includ-
ing inaccurate diagnoses or recording of 
data, could not be determined retro-
spectively.
Some important lessons have been 
learned (Box 1). Results of this analysis 
show limited accuracy and complete-
ness in clinic-level reporting, and so 
support the WHO recommendation 
that ART M&E tools be kept to a 
minimum and focus on critical indica-
tors. Ongoing supervision is critical to 
ensure quality data during scale-up, 
and decentralization of such capacity-
building activities may help to ensure 
sustainability of these efforts. Allocation Lessons from the field
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Résumé
Evaluation de la qualité des données agrégées par les centres de traitement antirétroviral au Malawi
Problématique Les programmes nationaux de traitement 
antirétroviral (ART) étant en phase d’élargissement, il est essentiel 
de disposer en temps utile d’informations complètes et exactes 
pour la surveillance des sites et la planification nationale. On ne 
sait souvent pas si les rapports compilés indépendamment par les 
établissements dispensant des traitements ART sont complets et 
exacts.
Démarche Les auteurs de cette étude ont évalué la qualité des 
données résumées et agrégées par trimestre pour la période avril-
juin 2006 provenant des rapports des établissements dispensant 
des traitements ART (« rapports de site ») par comparaison 
avec celle des données résumées de référence, compilées 
indépendamment pour ces établissements par l’équipe de 
supervision du Ministère de la santé (« rapport de supervision »). Ils 
ont également comparé la complétude et l’exactitude des principaux   
paramètres d’enregistrement des cas et d’issue du traitement. 
Les données ont été considérées comme inexactes s’il manquait 
des paramètres dans les rapports des sites ou si les valeurs des 
paramètres différaient de plus de 5 % des valeurs indiquées par 
les rapports de supervision. En outre, les auteurs ont comparé les 
résumés nationaux établis à partir de deux sources de données.
Contexte local La surveillance et l’évaluation du programme 
national de traitement ART du Malawi s’appuient sur les outils 
recommandés par l’OMS pour la surveillance ART. Elles prévoient 
une carte informatisée pour chaque patient sous traitement ART et un 
registre des patients pour chaque établissement dispensant ce type 
de traitement. Chaque trimestre, les sites réalisent des analyses de 
cohortes cumulatives et des équipes du Ministère de la santé effectuent   
des visites de supervision dans tous les sites ART du secteur public 
pour s’assurer de la qualité des données rapportées.
Modifications pertinentes La plupart des sites disposent de 
données complètes pour l’enregistrement des cas et les issues 
du traitement ; néanmoins, nombre d’entre eux ne fournissent pas 
des données exactes sur plusieurs points critiques, et notamment 
les raisons du placement sous traitement, l’issue du traitement et 
le schéma thérapeutique. Le résumé national à partir des rapports 
des sites a fait apparaître une sous-comptabilisation de 12 % du 
nombre total de personnes dans le pays sous traitement de première 
intention. Plusieurs caractéristiques au niveau des établissements 
sont associées à la qualité des données.
Enseignements tirés Si de nombreux sites sont en mesure de 
générer des résumés de données complets, leurs rapports ne sont 
pas encore suffisamment exacts pour la surveillance nationale. 
Le Ministère de la santé et ses partenaires doivent continuer 
à définir et à appuyer des interventions comme la supervision 
de soutien afin de renforcer la capacité des sites à conserver 
et à compiler des données de qualité et de garantir ainsi la 
disponibilité d’informations exactes pour la surveillance des sites   
et la planification nationale.
Resumen
Evaluación de la calidad de los datos reunidos por los centros de tratamiento antirretroviral en Malawi
Problema A medida que se expanden los programas nacionales 
de tratamiento antirretroviral (TAR), es fundamental contar con 
información completa, puntual y exacta para la vigilancia de 
los centros y la planificación nacional. Sin embargo, a menudo 
se desconoce la exactitud e integridad de los datos reunidos 
independientemente por los centros de TAR.
Enfoque Se evaluó la calidad de los datos agregados trimestrales 
que habían compilado y notificado los centros de TAR para 
el periodo de abril a junio de 2006 («informe del centro»),   
comparándolos con los datos resumidos «de referencia» reunidos 
independientemente por el equipo de supervisón del Ministerio 
de Salud («informe de supervisión»). Se compararon la integridad 
of dedicated trained personnel is critical 
to maintaining quality patient records 
and M&E data collection. An electronic 
data system that includes mechanisms 
to improve data quality (e.g. numerical 
validation, bounds checking, alerts) may 
facilitate site-level data management and 
reporting; this is currently being piloted 
in four district hospitals in Malawi. 
Finally, Malawi has had good success in 
simple incentives (e.g. certificates) for   
sites with good data quality. Such factors 
appear to motivate sites to maintain or 
improve data quality. As ART continues 
to scale-up, Malawi’s ART programme 
must ensure systems are in place to gen-
erate critical national information.  ■
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y exactitud de variables clave del registro de casos y de los 
resultados, y se decidió considerar inexactos los datos de los 
informes de los centros cuando las variables analizadas no   
constasen o difiriesen en más de un 5% de las consignadas en 
los informes de supervisión. Procedimos asimismo a comparar 
las cifras recapitulativas nacionales obtenidas a partir de esas dos 
fuentes de datos.
Contexto local La vigilancia y evaluación del programa nacional 
de TAR de Malawi está basada en los instrumentos recomendados 
por la OMS para la vigilancia del TAR. Ello incluye una ficha 
maestra para cada paciente sometido a TAR y un registro por 
paciente en cada centro de TAR. Cada trimestre, los centros 
realizan análisis de cohortes acumulativos y equipos del Ministerio   
de Salud realizan visitas de supervisión a todos los centros 
de TAR del sector público para verificar la calidad de los datos 
notificados.
Cambios destacables La mayoría de los centros disponían 
de datos completos en lo relativo al registro de casos y los 
resultados; sin embargo, muchos centros no aportaron datos 
precisos en varios campos cruciales, como la razón para 
comenzar el tratamiento, los resultados y el régimen. El resumen 
nacional basado en los informes de los centros subestimó en un 
12% el total nacional de personas bajo tratamiento de primera 
línea. La calidad de los datos estaba relacionada con diversas   
características de los centros.
Enseñanzas extraídas Si bien muchos de los centros pueden 
generar datos recapitulativos completos, los informes de los 
centros aún no tienen la exactitud exigible para la vigilancia 
nacional. El Ministerio de Salud y sus asociados deberían seguir 
identificando y apoyando intervenciones tales como la supervisión 
de apoyo a fin de desarrollar la capacidad de los centros para 
mantener y reunir datos de calidad de modo que pueda disponerse 
de información precisa para la vigilancia de los centros y la   
planificación nacional.
صخلم
يولام في ةيرقهقلا تاسويرفلاب ينباصلما ةجلاعم تادايع في ةعَّمجلما تايطعلما ةدوج ميـيقت
 تاسويرفلاب ينباصلما ةجلاعلم ةينطولا جمابرلاب ضوهنلا راطإ في :ةلكشلما
 تقولا نع برعتو ةقيقدو ةلمكتسم تايطعلما نوكت نأ نم دبلا ةيرقهقلا
 ةفرعم رذعتي ام ًايرثكو .ينطولا ديعصلا لىع طيطختلاو دصرلا عقولم مئلالما
 ةيرقهقلا تاسويرفلا ةجلاعم قفارم اهعمجت يتلا ريراقتلا لماك ىدمو ةقد
.درفنم لكشب
 ةعمجلماو ةصخللما تايطعلما ةدوج ةساردلا هذه في نوثحابلا مِّيقي :بولسلأا
 غلبت يتلاو ،وينوي/ناريزحو ويام/رايأو ليربأ/ناسين يه روهش ةثلاث للاخ
 يرـياعلماب اهتنراقمو )ةيناديم ريراقت( ةيرقهقلا تاسويرفلا ةجلاعم قفارم اهنع
 لَبِق نم لقتسم لكشب قفارلما اهتعمج يتلا ةصخللما تايطعملل ةيبهذلا
 ىدم ةنراقملل تَعِضْخُأو .)فاشرلإا ريرقت( ةحصلا ةرازو نم فاشرلإا قيرف
 دقو ،جئاتنلاب ةصاخلا تايرغتلماو تلااحلل ةيسيئرلا تلاجسلا لماتكاو ةقد
 ةفلتخم تناك وأ ةرفاوتم تايرغتلما نكت لم اذإ ةحيحص يرغ تايطعلما تبرتعا
 تاصخللما نوثحابلا نراق مث ،فاشرلإا ريراقت نم 5% لىع ديزي رادقبم
.تايطعلما رداصم نم نيردصم نم اهيلع اولصح يتلا ةينطولا
 ينباصلما  ةجلاعلم  ينطولا  جمانبرلا  ميـيقتو  دصر  زكتري  :ليحلما  عقولما
 ةحصلا ةمظنم اهمادختساب صيوت ةادأ لىع يولام في ةيرقهقلا تاسويرفلاب
 ىَّقلتي ضيرم لكل ةيسيئر ةقاطب  نمضتت،ةجلاعلما كلت دصرل ةيلماعلا
 ةجلاعملل قفرم لك في ضيرملل رخآ ًلاجسو ةيرقهقلا تاسويرفلل ةجلاعلما
 يمكاترلا ليلحتلا عقاولما لمكتست روهش ةثلاث لكو .ةيرقهقلا تاسويرفلا نم
 ةجلاعلما عقاوم لىع ةيفاشرإ تارايز ةحصلا ةرازو نم ةقرفأ يرجتو ،بارتلأل
 تايطعلما ةدوج نم دُّكأتلل ماعلا عاطقلل ةعباتلا ةيرقهقلا تاسويرفلا نم
 .اهنع غَّلبلما
 ةصاخلا تايطعلماو تاقاطبلا ليجست عقاولما مظعم تلمكتسا دقل :تايرغتلا
 لوقحلا نم ددعل ةقيقدلا تايطعلما نع غلبي لم اهنم يرثكلا نأ لاإ ،جئاتنلاب
 ماظنو ،ةجيتنلاو ،ءدبلا ببس لمشت يتلاو تايطعلما في ةيمهلأا ةغلابلا
 صقن لىإ ةيناديلما ريراقتلل ةينطولا ةصلاخلا مادختسا ىَّدأ دقو .ةجلاعلما
 نوجلاعي نيذلا صاخشلأل ليماجلإا ينطولا ددعلا في 12% هرادقم بياسح
 قفرلما ىوتسم صئاصخ نم ديدعلا ينب ةقلاع كانهو ،لولأا طخلا ةيودأب
.تايطعلما ةدوجو
 لىع لوصحلا عقاولما نم ديدعلا ةعاطتساب نأ مغر :ةدافتسلما سوردلا
 يرغ قفارلما نع ةرداصلا ريراقتلا ةقد نإف تايطعلما لوح ةلماك تاصلاخ
 لمعلا ةلصاوم اهئاكشر لىعو ةحصلا ةرازو لىع يغبنيو .ينطولا دصرلل ةيفاك
 في تاردقلا ءانب ةيغب معادلا فاشرلإا ليبق نم تلاخادُمـلا لىع فُّرعتلل
 كلتل معدلا ميدقتو ةدوجلا ةعيفرلا تايطعلما عمج في رارمتسلال عقاولما
 طيطختلاو نياديلما دصرلل ةقيقدلا تامولعلما رفاوت نماضل تلاخادُمـلا
.ينطولا
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